瑞典 65 岁以下未接种疫苗的首次检测呈阳性且无合并症的成年人在 Omicron 和 Omicron 前感染 SARS-CoV-2 的严重程度。

IF 4.7 3区 医学 Q1 INFECTIOUS DISEASES
Erik Wahlström , Daniel Bruce , Anna M. Bennet-Bark , Sten Walther , Håkan Hanberger , Kristoffer Strålin
{"title":"瑞典 65 岁以下未接种疫苗的首次检测呈阳性且无合并症的成年人在 Omicron 和 Omicron 前感染 SARS-CoV-2 的严重程度。","authors":"Erik Wahlström ,&nbsp;Daniel Bruce ,&nbsp;Anna M. Bennet-Bark ,&nbsp;Sten Walther ,&nbsp;Håkan Hanberger ,&nbsp;Kristoffer Strålin","doi":"10.1016/j.jiph.2024.102502","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The COVID-19 pandemic has had several phases with varying characteristics. We aimed to compare severity outcomes in different phases in a population with limited bias from risk factors.</p></div><div><h3>Methods</h3><p>In a nationwide observational study of all unvaccinated first-time COVID-19 test positive individuals in Sweden aged 18–64 years without comorbidity, from week 45 of 2020 to week 5 of 2022, variant periods with certain variants constituting ≥ 92 % of all whole genome-sequenced cases nationwide, were compared regarding hospitalisation (with main discharge code of COVID-19), severe illness (use of high-flow nasal oxygen or admission to intensive care unit), and death due to COVID-19. Logistic regression was used to estimate odds ratios (ORs) for comparison of these outcomes between variant periods, using adjustments for variant period, age, sex, country of birth, place of residence, income, and education.</p></div><div><h3>Findings</h3><p>The study included 789,133 individuals, including 15,145 hospitalised individuals. Among all individuals, the adjusted ORs for hospitalisation were 1.7 for the Alpha period vs the Pre-variant period (week 45–52 2020), 1.8 for the Delta period vs the Alpha period, and 0.1 for the Omicron period vs the Delta period (all comparisons significant). Among hospitalised individuals, the adjusted ORs for severe illness were 1.4 for the Alpha period vs the Pre-variant period, 1.7 for the Delta period vs the Alpha period, and 0.5 for the Omicron period vs the Delta period (all comparisons significant), and the adjusted ORs for death were 1.1 for the Alpha period vs the Pre-variant period (non-significant), 1.8 for the Delta period vs the Alpha period (significant), and 0.1 for the Omicron period vs the Delta period (non-significant).</p></div><div><h3>Interpretation</h3><p>In this population with limited bias from risk factors, vaccination, and previous infection, disease severity increased from the pre-variant to the Delta period and then decreased with the Omicron period, among all individuals and among hospitalised individuals. These severity outcome differences should be considered when the pandemic is evaluated.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"17 9","pages":"Article 102502"},"PeriodicalIF":4.7000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124002363/pdfft?md5=602858c57050e00683510f4feadf21c0&pid=1-s2.0-S1876034124002363-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Severity outcomes of SARS-CoV-2 infection in the Omicron and pre-Omicron periods, in unvaccinated first-time test positive adults less than 65 years old without comorbidity, in Sweden\",\"authors\":\"Erik Wahlström ,&nbsp;Daniel Bruce ,&nbsp;Anna M. Bennet-Bark ,&nbsp;Sten Walther ,&nbsp;Håkan Hanberger ,&nbsp;Kristoffer Strålin\",\"doi\":\"10.1016/j.jiph.2024.102502\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The COVID-19 pandemic has had several phases with varying characteristics. We aimed to compare severity outcomes in different phases in a population with limited bias from risk factors.</p></div><div><h3>Methods</h3><p>In a nationwide observational study of all unvaccinated first-time COVID-19 test positive individuals in Sweden aged 18–64 years without comorbidity, from week 45 of 2020 to week 5 of 2022, variant periods with certain variants constituting ≥ 92 % of all whole genome-sequenced cases nationwide, were compared regarding hospitalisation (with main discharge code of COVID-19), severe illness (use of high-flow nasal oxygen or admission to intensive care unit), and death due to COVID-19. Logistic regression was used to estimate odds ratios (ORs) for comparison of these outcomes between variant periods, using adjustments for variant period, age, sex, country of birth, place of residence, income, and education.</p></div><div><h3>Findings</h3><p>The study included 789,133 individuals, including 15,145 hospitalised individuals. Among all individuals, the adjusted ORs for hospitalisation were 1.7 for the Alpha period vs the Pre-variant period (week 45–52 2020), 1.8 for the Delta period vs the Alpha period, and 0.1 for the Omicron period vs the Delta period (all comparisons significant). Among hospitalised individuals, the adjusted ORs for severe illness were 1.4 for the Alpha period vs the Pre-variant period, 1.7 for the Delta period vs the Alpha period, and 0.5 for the Omicron period vs the Delta period (all comparisons significant), and the adjusted ORs for death were 1.1 for the Alpha period vs the Pre-variant period (non-significant), 1.8 for the Delta period vs the Alpha period (significant), and 0.1 for the Omicron period vs the Delta period (non-significant).</p></div><div><h3>Interpretation</h3><p>In this population with limited bias from risk factors, vaccination, and previous infection, disease severity increased from the pre-variant to the Delta period and then decreased with the Omicron period, among all individuals and among hospitalised individuals. These severity outcome differences should be considered when the pandemic is evaluated.</p></div>\",\"PeriodicalId\":16087,\"journal\":{\"name\":\"Journal of Infection and Public Health\",\"volume\":\"17 9\",\"pages\":\"Article 102502\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2024-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1876034124002363/pdfft?md5=602858c57050e00683510f4feadf21c0&pid=1-s2.0-S1876034124002363-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infection and Public Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1876034124002363\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Public Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876034124002363","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:COVID-19大流行分为几个阶段,其特征各不相同。我们旨在比较不同阶段人群的严重程度结果,因为风险因素造成的偏差有限:在一项全国范围的观察性研究中,我们对瑞典所有 18-64 岁首次 COVID-19 检测呈阳性且无合并症的未接种者进行了研究,研究时间为 2020 年第 45 周至 2022 年第 5 周,比较了因 COVID-19 而住院(主要出院代码为 COVID-19)、重症(使用高流量鼻氧或入住重症监护室)和死亡的变异期,其中某些变异占全国所有全基因组测序病例的比例≥ 92%。通过对不同时期、年龄、性别、出生国、居住地、收入和教育程度等因素进行调整,采用逻辑回归法估算出这些结果在不同时期间比较的几率比(ORs):研究共纳入 789 133 人,包括 15 145 名住院患者。在所有患者中,阿尔法期与变异前期(2020 年第 45-52 周)的住院调整 OR 值分别为 1.7、德尔塔期与阿尔法期的调整 OR 值分别为 1.8、奥米克隆期与德尔塔期的调整 OR 值分别为 0.1(所有比较均显著)。在住院患者中,阿尔法期与变异前期相比,重症的调整OR为1.4,德尔塔期与阿尔法期相比,重症的调整OR为1.7,奥克隆期与德尔塔期相比,重症的调整OR为0.5(所有比较均显著),阿尔法期与变异前期相比,死亡的调整OR为1.1(不显著),德尔塔期与阿尔法期相比,死亡的调整OR为1.8(显著),奥克隆期与德尔塔期相比,死亡的调整OR为0.1(不显著):在这一受风险因素、疫苗接种和既往感染影响有限的人群中,从变异前到德尔塔期,所有个体和住院个体的疾病严重程度均有所上升,然后随着奥米克伦期的到来而下降。在对大流行进行评估时,应考虑到这些严重程度结果的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Severity outcomes of SARS-CoV-2 infection in the Omicron and pre-Omicron periods, in unvaccinated first-time test positive adults less than 65 years old without comorbidity, in Sweden

Background

The COVID-19 pandemic has had several phases with varying characteristics. We aimed to compare severity outcomes in different phases in a population with limited bias from risk factors.

Methods

In a nationwide observational study of all unvaccinated first-time COVID-19 test positive individuals in Sweden aged 18–64 years without comorbidity, from week 45 of 2020 to week 5 of 2022, variant periods with certain variants constituting ≥ 92 % of all whole genome-sequenced cases nationwide, were compared regarding hospitalisation (with main discharge code of COVID-19), severe illness (use of high-flow nasal oxygen or admission to intensive care unit), and death due to COVID-19. Logistic regression was used to estimate odds ratios (ORs) for comparison of these outcomes between variant periods, using adjustments for variant period, age, sex, country of birth, place of residence, income, and education.

Findings

The study included 789,133 individuals, including 15,145 hospitalised individuals. Among all individuals, the adjusted ORs for hospitalisation were 1.7 for the Alpha period vs the Pre-variant period (week 45–52 2020), 1.8 for the Delta period vs the Alpha period, and 0.1 for the Omicron period vs the Delta period (all comparisons significant). Among hospitalised individuals, the adjusted ORs for severe illness were 1.4 for the Alpha period vs the Pre-variant period, 1.7 for the Delta period vs the Alpha period, and 0.5 for the Omicron period vs the Delta period (all comparisons significant), and the adjusted ORs for death were 1.1 for the Alpha period vs the Pre-variant period (non-significant), 1.8 for the Delta period vs the Alpha period (significant), and 0.1 for the Omicron period vs the Delta period (non-significant).

Interpretation

In this population with limited bias from risk factors, vaccination, and previous infection, disease severity increased from the pre-variant to the Delta period and then decreased with the Omicron period, among all individuals and among hospitalised individuals. These severity outcome differences should be considered when the pandemic is evaluated.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Infection and Public Health
Journal of Infection and Public Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -INFECTIOUS DISEASES
CiteScore
13.10
自引率
1.50%
发文量
203
审稿时长
96 days
期刊介绍: The Journal of Infection and Public Health, first official journal of the Saudi Arabian Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences and the Saudi Association for Public Health, aims to be the foremost scientific, peer-reviewed journal encompassing infection prevention and control, microbiology, infectious diseases, public health and the application of healthcare epidemiology to the evaluation of health outcomes. The point of view of the journal is that infection and public health are closely intertwined and that advances in one area will have positive consequences on the other. The journal will be useful to all health professionals who are partners in the management of patients with communicable diseases, keeping them up to date. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on infection control and public health, as well as emphasizing our focus on supporting the needs of public health practitioners. It is our aim to improve healthcare by reducing risk of infection and related adverse outcomes by critical review, selection, and dissemination of new and relevant information in the field of infection control, public health and infectious diseases in all healthcare settings and the community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信